首页> 外文OA文献 >Intracellular Time Course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary Delivery of Inhalable Microparticles to Mice▿
【2h】

Intracellular Time Course, Pharmacokinetics, and Biodistribution of Isoniazid and Rifabutin following Pulmonary Delivery of Inhalable Microparticles to Mice▿

机译:吸入性微粒向小鼠肺部递送后异烟肼和利福布汀的细胞内时程,药代动力学和生物分布

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Intracellular concentrations of isoniazid and rifabutin resulting from administration of inhalable microparticles of these drugs to phorbol-differentiated THP-1 cells and the pharmacokinetics and biodistribution of these drugs upon inhalation of microparticles or intravenous administration of free drugs to mice were investigated. In cultured cells, both microparticles and dissolved drugs established peak concentrations of isoniazid (∼1.4 and 1.1 μg/106 cells) and rifabutin (∼2 μg/ml and ∼1.4 μg/106 cells) within 10 min. Microparticles maintained the intracellular concentration of isoniazid for 24 h and rifabutin for 96 h, whereas dissolved drugs did not. The following pharmacokinetic parameters were calculated using WinNonlin from samples obtained after inhalation using an in-house apparatus (figures in parentheses refer to parameters obtained after intravenous administration of an equivalent amount, i.e., 100 μg of either drug, to parallel groups): isoniazid, serum half-life (t1/2) = 18.63 ± 5.89 h (3.91 ± 1.06 h), maximum concentration in serum (Cmax) = 2.37 ± 0.23 μg·ml−1 (3.24 ± 0.57 μg·ml−1), area under the concentration-time curve from 0 to 24 h (AUC0-24) = 55.34 ± 13.72 μg/ml−1 h−1 (16.64 ± 1.80 μg/ml−1 h−1), and clearance (CL) = 63.90 ± 13.32 ml·h−1 (4.43 ± 1.85 ml·h−1); rifabutin, t1/2 = 119.49 ± 29.62 h (20.18 ± 4.02 h), Cmax = 1.59 ± 0.01 μg·ml−1 (3.47 ± 0.33 μg·ml−1), AUC0-96 = 109.35 ± 14.78 μg/ml−1 h−1 (90.82 ± 7.46 μg/ml−1 h−1), and CL = 11.68 ± 7.00 ml·h−1 (1.03 ± 0.11 ml·h−1). Drug targeting to the lungs in general and alveolar macrophages in particular was observed. It was concluded that inhaled microparticles can reduce dose frequency and improve the pharmacologic index of the drug combination.
机译:研究了将这些药物的可吸入微粒给予佛波醇分化的THP-1细胞后所产生的异烟肼和利福布汀的细胞内浓度,以及吸入微粒或向小鼠静脉内给予免费药物后这些药物的药代动力学和生物分布。在培养的细胞中,微粒和溶解的药物都在10分钟内建立了异烟肼(〜1.4和1.1μg/ 106细胞)和利福布汀(〜2μg/ ml和〜1.4μg/ 106细胞)的峰值浓度。微粒将异烟肼的细胞内浓度维持24小时,而利福布汀则维持96小时,而溶解的药物则没有。使用WinNonlin从内部设备吸入后获得的样品中计算出以下药代动力学参数(括号中的数字是指向平行组静脉内注射等量的100克任何一种药物后获得的参数):异烟肼,血清半衰期(t1 / 2)= 18.63±5.89 h(3.91±1.06 h),血清最大浓度(Cmax)= 2.37±0.23μg·ml-1(3.24±0.57μg·ml-1),从0到24 h(AUC0-24)的浓度时间曲线= 55.34±13.72μg/ ml-1 h-1(16.64±1.80μg/ ml-1 h-1),清除率(CL)= 63.90±13.32 ml·h-1(4.43±1.85 ml·h-1);利福布汀,t1 / 2 = 119.49±29.62 h(20.18±4.02 h),Cmax = 1.59±0.01μg·ml-1(3.47±0.33μg·ml-1),AUC0-96 = 109.35±14.78μg/ ml-1 h-1(90.82±7.46μg/ ml-1 h-1),CL = 11.68±7.00 ml·h-1(1.03±0.11 ml·h-1)。观察到一般针对肺,特别是肺泡巨噬细胞的药物。得出的结论是,吸入微粒可以降低剂量频率并改善药物组合的药理指数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号